We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 438

Australian court finds human gene mutation to be patentable

  • Shook Hardy & Bacon LLP
  • -
  • Australia, USA
  • -
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be

Vaccine developer agrees to settle shareholder litigation

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 11 2014

A putative class action instituted by three shareholders against the nowbankrupt biotechnology company Biovest International, Inc., alleging

International funding agencies to support infectious disease research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 11 2014

Under the Ecology and Evolution of Infectious Diseases program, three U.S. agenciesthe National Institutes of Health (NIH), National Science

KC Animal Health Corridor claims 56 percent of total worldwide sales

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 11 2014

An asset survey unveiled to animal health industry leaders during recent Kansas City (KC) Animal Health Corridor "homecoming" activities reportedly

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 11 2014

The U.S. Patent and Trademark Office (USPTO) seeks comments on the estimated time burdens of revisions to a currently approved information collection

FDA releases clinical trial action plan

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 11 2014

The U.S. Food and Drug Administration (FDA) has issued a 27-point action plan aimed at improving diversity in clinical trials. While the numbers of

“Purple Book” sets forth approved biologicals, will expand to biosimilars

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 11 2014

The U.S. Food and Drug Administration (FDA) has released lists of reference biological products regulated by the Center for Drug Evaluation and

Government funding to support development of Ebola treatment

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 21 2014

The U.S. National Institute of Allergy and Infectious Diseases has reportedly exercised options to conduct Phase 1 human-safety trials and non-human

FDA issues guidance on unique medical device ID system

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 21 2014

The U.S. Food and Drug Administration (FDA) has issued guidance to help industry, particularly small businesses, label their medical devices in

Physicians urge FDA to allow distinctive names for biosimilars

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 21 2014

A coalition of organizations representing specialist physicians and individual physicians have authored a letter to U.S. Food and Drug Administration